Current global surveillance data from the WHO and CDC show SARS-CoV-2 circulating at low endemic levels, with stable positivity rates below 10% in most regions and no exponential growth in cases or hospitalizations as of October 2026. Existing immunity from vaccination and prior infection, combined with effective treatments, has prevented the emergence of variants capable of triggering a new pandemic-level surge. MERS-CoV reports remain minimal, limited to isolated cases in the Arabian Peninsula. Trader consensus on the low probability of a new coronavirus pandemic reflects this sustained epidemiological stability and robust genomic monitoring. However, a novel bat-derived merbecovirus or highly mutated SARS-CoV-2 lineage with enhanced human ACE2 binding and immune evasion could still shift outcomes if surveillance detects sustained transmission.